Last updated: 6 June 2024 at 4:15pm EST

Nancy Miller-Rich Net Worth



Nancy Miller-Rich biography

Nancy Miller-Rich serves as Independent Director of the Company. Ms. Miller-Rich has 35 years of experience in the healthcare industry, with significant expertise in business development and commercial strategy. Since September 2017, Ms. Miller-Rich has served as a consultant to the pharmaceutical industry. Previously, Ms. Miller-Rich served in a number of leadership roles at Merck & Co., Inc. and, prior to the merger of the two companies, at Schering-Plough Corporation, including most recently as Senior Vice President, Global Human Health Business Development & Licensing, Strategy and Commercial Support from November 2013 to September 2017 and as Group Vice President, Consumer Care Global New Ventures and Strategic Commercial Development from January 2007 to November 2013. Prior to joining Schering-Plough in 1990, Ms. Miller-Rich served in a variety of commercial and marketing roles at Sandoz Pharmaceuticals and Sterling Drug, Inc. She is currently a director of UDG Healthcare plc, as well as a board member of a number of private and not-for-profit entities. She received her B.S. in Business Administration, Marketing from Ithaca College in Ithaca, New York.

What is the salary of Nancy Rich?

As the Independent Director of Intercept Pharmaceuticals Inc, the total compensation of Nancy Rich at Intercept Pharmaceuticals Inc is $318,856. There are 16 executives at Intercept Pharmaceuticals Inc getting paid more, with Mark Pruzanski having the highest compensation of $6,615,780.



How old is Nancy Rich?

Nancy Rich is 61, she's been the Independent Director of Intercept Pharmaceuticals Inc since 2018. There are 3 older and 21 younger executives at Intercept Pharmaceuticals Inc. The oldest executive at Intercept Pharmaceuticals Inc is Keith Gottesdiener, 66, who is the Independent Director.

What's Nancy Rich's mailing address?

Nancy's mailing address filed with the SEC is C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, LEXINGTON, MA, 02421.

Insiders trading at Intercept Pharmaceuticals Inc

Over the last 12 years, insiders at Intercept Pharmaceuticals Inc have traded over $1,530,243,701 worth of Intercept Pharmaceuticals Inc stock and bought 2,408,920 units worth $77,118,364 . The most active insiders traders include Srinivas Akkaraju, Jonathan Silverstein, eFrancesco Micheli. On average, Intercept Pharmaceuticals Inc executives and independent directors trade stock every 10 days with the average trade being worth of $1,114,673. The most recent stock trade was executed by Srinivas Akkaraju on 10 March 2021, trading 237,000 units of ICPT stock currently worth $5,017,290.



What does Intercept Pharmaceuticals Inc do?

we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.



What does Intercept Pharmaceuticals Inc's logo look like?

Intercept Pharmaceuticals Inc logo

Intercept Pharmaceuticals Inc executives and stock owners

Intercept Pharmaceuticals Inc executives and other stock owners filed with the SEC include: